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The manuscript by Romer et al. (2004)
describes a preclinical trial of a novel
small molecule inhibitor of smoothened
(Smo) in a genetically engineered mouse
model for medulloblastoma. The authors
have used the well-described Ptc1+/−,
p53−/− mice that develop histologically
accurate medulloblastoma within 12
weeks (Wetmore et al., 2001). Cultured
cells and allografts from
medulloblastomas arising in
the Ptc1+/−, p53−/− mice have
been used to test antitumor
activity of the natural product
cyclopamine (Berman et al.,
2002). However, such sys-
tems have the potential to be
misleading, as the molecular
pathways important for tumor
growth in situ may be altered
in cultured tumor cells and
xenografts. Here, Romer and
colleagues used the tumor-
bearing, genetically engi-
neered mice themselves to
test a novel compound
HhAntag. This compound
was identified in a cell-based
screen as blocking Smo with
tenfold higher affinity than
cyclopamine. This work is
particularly significant as it
illustrates the use of geneti-
cally engineered mouse mod-
els of cancer in the process of
drug development.
It is clear that developing
rational therapeutic approach-
es for medulloblastoma is essential.
Although many children with medulloblas-
tomas are cured of their tumor by surgery,
radiation, and chemotherapy, they are fre-
quently devastated by the treatment. This
tumor is an excellent example of how can-
cer can be an aberration of normal devel-
opment (Raffel, 2004). Medulloblastomas
arise from the precursors of the internal
granule cells. Originally occupying the
external germinal cell layer, these cells
are driven to proliferate by sonic hedge-
hog (Shh) signaling. Under normal condi-
tions, they then begin to differentiate, and
then migrate inward to their final resting
place, the internal granule cell layer
(Ingham and McMahon, 2001). Several
lines of evidence indicate that a subset of
human medulloblastomas are caused by
inappropriately continued SHH signaling
and a derailment of normal differentiation.
Mouse models of this disease have been
particularly informative in this regard.
Either gain of Shh signaling or loss of Ptc1
cooperates with other alterations, leading
to the formation of tumors with histological
similarities to the human tumors (Figure
1), indicating that the SHH signaling path-
way can be causally related to medul-
loblastoma genesis (Wetmore et al.,
2001, Rao et al., 2004, Goodrich et al.,
1997). Further, the gene expression pro-
files of many of the mouse models of
medulloblastomas show a high degree of
similarity to the expression profile of the
cerebellum five days after birth, the point
where the Shh-driven EGL proliferation is
at its highest in normal development (Lee
et al., 2003). Given all of this, it is a rea-
sonable assumption that the SHH signal-
ing pathway is central to medulloblastoma
biology.
The problem of SHH signaling in
medulloblastomas is essentially one step
removed from BCR/ABL in CML or Kit in
GIST, where a single disregulated sig-
naling pathway is causally
related to the formation of the
tumor. In the case of CML
and GIST, the presence of
the translocation or mutation
identifies it as the inciting
event, and as the tumors
evolve, they maintain depen-
dence on that abnormal 
signaling activity. In these
tumors, small molecule
blockade of the mutated gene
products is therapeutically
effective. The general con-
cept of a tumor’s dependence
on the product of the original
genetic event is supported by
several examples of experi-
mentally induced mouse
tumors (Chin et al., 1999,
Felsher and Bishop, 1999). In
the case of most solid human
tumors, however, the inciting
event is not known, and
therefore, small molecule
inhibitors of the actual mutat-
ed gene product are unavail-
able. This is the case in a
large subset of medulloblas-
tomas. Although there are mutations
found in PTC1 in approximately 10% of
the tumors, the elevated SHH signaling
seen in a larger subset of medulloblas-
tomas is frequently not explained by
mutation, and the pharmacologic inter-
vention available does not directly attack
the mutated gene product. However,
mutations in different components of the
Shh pathway, which lead to inappropriate
activity of the pathway, have been identi-
fied and may account for most of the
medulloblastomas with high GLI1
expression. Therefore, Shh signaling
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Histologically accurate mouse models of human cancers generated by somatic or germline genetic modification strategies
recapitulate the genetic alterations found in human tumors. In this issue of Cancer Cell, Romer et al. (2004) test a novel sig-
naling inhibitor in a genetically defined mouse medulloblastoma and show the utility of these models in drug development.
They demonstrate that targeting signaling components downstream of tumor initiating mutations can be an effective ther-
apeutic strategy for solid tumors.
Figure 1. Aberrant SHH signaling and the development of 
medulloblastoma
Hyperactivation of the SHH signaling pathway leading to medul-
loblastoma formation can occur by either inappropriately elevated
SHH ligand binding to PTC and inactivating its tonic repression of SMO
(A) or loss of PTC (B). Both mechanisms lead to the formation of medul-
loblastomas in mice. Romer et al. have used the PTC loss mouse
model for medulloblastoma formation to verify that the novel SMO
inhibitor HhAntag could be therapeutically useful for medulloblas-
tomas in humans (C) (red arrow). MRI courtesy of Dr. Mark
Souweidane.
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likely plays a central role in these tumors,
which makes pharmacological blockade
of the pathway an extremely attractive
strategy. The data from this manuscript,
in concert with other publications,
strongly suggests that such a strategy
may well work in a subset of medul-
loblastoma patients, and in other tumors
that depend on SMO activity for growth
Perhaps more importantly, these
studies highlight the evolution of thought
regarding the use of mice in the under-
standing of cancer and development of
novel therapies. The majority of preclini-
cal work has used xenografts, cell lines
derived from human tumors that are
maintained in culture and implanted into
the flank or orthotopic site of an immuno-
compromised mouse. The goal of such
studies has been to determine if the drug
in question shrinks the grafted tumors or
extends the lifespan of the mice harbor-
ing them. Although these models are
standardized and generate reproducible
tumors, they have been less predictive of
human response to drugs than one would
like. Romer et al. provide an explanation
for why such an approach may ultimately
fail for those developing compounds that
target the Shh pathway in medulloblas-
toma. They found that the pathway is
promptly downregulated when cells are
placed in culture. Further, they demon-
strate that the antiproliferative effects of
cyclopamine reported previously reflect a
nonspecific toxicity of high compound
concentrations as opposed to the specific
effect of blocking the Shh pathway.
The new genetically defined mouse
models of human cancer have major
potential advantages over xenografts in
preclinical trials (Holland, 2004). First,
genetic models by definition recapitulate
genetic events that are causally related
to the formation of the tumor, and offer a
proof-of-principle test of critical targets
for therapy. The SHH signaling pathway
has now been validated as a therapeutic
target in medulloblastoma using this new
approach. Second, genetically induced
tumors arise in situ and frequently have
histologies very similar to or indistin-
guishable from the human counterparts,
as in the case of the medulloblastomas
reported here. By contrast, xenografts
rarely have histological similarity to the
tumors from which they were originally
derived. Finally, and most importantly for
this work, the requirement for specific
biologic activities in the context of
defined inciting events can only be
addressed in systems where the causal
genetic events are known.
These genetic mouse models of can-
cer may be most useful in defining gen-
eral rules for the dependence of tumors
on individual and combined biologic
pathways. The simplistic view of a
response to therapy being tumor shrink-
age or prolonged survival of a cohort of
mice may be replaced with more specific
questions, such as molecular efficacy,
cell cycle progression, regional cell
death, and morphologic conversion as
response to therapy. Preclinical trials of
this nature may also identify surrogate
markers for effective intervention that
could be used in human trials.
The differences in drug metabolism
between mouse and human suggest that
mice are not likely to identify the best
drug for human use from a group that all
attack the same target with similar affini-
ty. However, mouse models may very
well tell us that a particular target or
pathway is important to address thera-
peutically in a particular molecular sub-
set of human tumors. Further, such
preclinical trials will likely be able to
determine whether novel drugs can hit
their targets and achieve biologic effects
in vivo. In the case of medulloblastomas
and SHH signaling, we can guess that
blockade of the pathway by some small
molecule may be effective in the subset
of human medulloblastomas that are dri-
ven by SHH signaling. The best drug for
that purpose in humans may not yet be
identified, although the efficacy of
HhAntag in vivo presented here is quite
encouraging. The substantial power of
mouse modeling has been developed by
the collective scientific community over
the last 20 years primarily for the pur-
pose of understanding biology. Hopefully,
studies such as these are now opening
the door for uses of this technology to be
applied directly toward improvement of
the human condition.
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